BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2737080)

  • 1. Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.
    Felmingham D; Robbins MJ; Baskerville AJ; Sanghrajka MD; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1989; 15(2):59-62. PubMed ID: 2737080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
    Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN
    Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.
    Ko KS; Song JH; Lee MY; Park S; Kwon KT; Heo ST; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):337-41. PubMed ID: 16631337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefdinir: in vitro activity study and effect of human serum.
    García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
    Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
    Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ertapenem against selected respiratory pathogens.
    Marchese A; Gualco L; Schito AM; Debbia EA; Schito GC
    J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.